Search

Displaying results 4001 - 4010 of 7502 in total
  1. Drug

    Paramethasone

    go.drugbank.com/drugs/DB01384
    Experimental

    It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less

  2. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  3. Drug

    Atinumab

    go.drugbank.com/drugs/DB17923
    Investigational

    ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.

  4. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  5. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver.

  6. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.

  7. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]

  8. Drug

    Amitraz

    go.drugbank.com/drugs/DB11373
    ExperimentalVet approved

    Amitraz is a non-systemic acaricide and insecticide. It was generated in 1969 by the Boots Co. in England. … Its insecticide effect is due to its agonistic activity in the alpha-adrenergic system, its interaction with the octopamine receptors in the central nervous system and its driven inhibition of the synthesis

    Synonyms: N,N'-(methyliminodimethylidyne)bis-2,4-xylidine
  9. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species. … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.

  10. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2.